Perindopril arginine: benefits of a new salt of the ACE inhibitor perindopril

References

• PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033–41
   PubMed Web of Science ®Google Scholar
• Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782–8
   PubMed Web of Science ®Google Scholar
• Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006;166:659–66
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895–906
   PubMed Web of Science ®Google Scholar
• Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338–45
   PubMed Web of Science ®Google Scholar
• Bertrand ME. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr Med Res Opin 2004;20:1559–69
   PubMed Web of Science ®Google Scholar
• Morishita T, Tsutsui M, Shimokawa H, et al. Long-term treatment with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease. Jpn J Pharmacol 2002;88:100–7
   PubMedGoogle Scholar
• Su JB, Barbe F, Crozatier B, et al. Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure. J Cardiovasc Pharmacol 1999;34:700–10
   PubMed Web of Science ®Google Scholar
• Devissaguet JP, Ammoury N, Devissaguet M, Perret L. Pharmacokinetics of perindopril and its metabolites in healthy volunteers. Fundam Clin Pharmacol 1990;4:175–89
   PubMed Web of Science ®Google Scholar
• Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev Cardiovasc Ther 2005;3:15–29
   PubMedGoogle Scholar
• Physicians’ Desk Reference, 55th edn. Montvale, NJ: Medical Economics Company, 2001
   Google Scholar
• Julius S, Cohn JN, Neutel J, et al. Antihypertensive utility of perindopril in a large, general practice-based clinical trial. J Clin Hypertens (Greenwich) 2004;6:10–17
   PubMedGoogle Scholar
• Poggi L, Renucci JF, Denolle T. Treatment of essential hyper-tension in general practice: an open-label study of 47,351 French hypertensive patients treated for one year with perindopril. Can J Cardiol 1994;10(Suppl D):21–24D
   Google Scholar
• Lechat P, Garnham SP, Desche P, Bounhoure JP. Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure. Am Heart J 1993;126:798–806
   PubMed Web of Science ®Google Scholar
• Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Melbourne Diabetic Nephropathy Study Group. BMJ 1991;302:210–16
   PubMedGoogle Scholar
• Ceconi C, Fox K, Remme WJ, et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2006;doi:10.1016/j.cardiores.2006.10.021
   Google Scholar
• National Institute for Health and Clinical Excellence (NICE) -British Hypertension Society (BHS). Hypertension: management of hypertension in adults in primary care. Available from www.nice.org.uk/CG034guidance. [Accessed 12 July 2006]
   Google Scholar
• Yoshinaga K, Saruta T, Abe K, et al. Clinical evaluation of monotherapy with perindopril, an ACE inhibitor, in the treatment of essential hypertension: double-blind parallel comparison with enalapril. J Clin Ther Medicines 1997;13:4259–97
   Google Scholar
• Telejko E. Stability of tablets and efficiency and safety of drug use in various situations [in Polish]. Farmacja Polska 2006;62:381–88
   Google Scholar
• ICH Steering Committee. Quality guidelines. Available from www.ich.org/cache/compo/363-272-1.html. [Accessed 9 May 2006]
   Google Scholar
• Dietz R, Feilner K, Gerst F, Grimm W. Drug stability testing. Classification of countries according to climatic zone. Drugs made in Germany 1993;36:99–103
   Google Scholar
• Al Omari MM, Abdelah MK, Badwan AA, Jaber AM. Effect of the drug-matrix on the stability of enalapril maleate in tablet formulations. J Pharm Biomed Anal 2001;25:893–902
   PubMed Web of Science ®Google Scholar
• al Zein H, Riad LE, Abd-Elbary A. Effect of packaging and storage on the stability of carbamazepine tablets. Drug Dev Ind Pharm 1999;25:223–7
   PubMedGoogle Scholar
• Reynolds JM, Rogers DH. Adjusting dissolution specifications for the variability induced by storage conditions. J Biopharm Stat 2000;10:425–31
   PubMedGoogle Scholar
• Stanisz B. Kinetics of degradation of quinapril hydrochloride in tablets. Pharmazie 2003;58:249–51
   PubMed Web of Science ®Google Scholar
• Stanisz B. Kinetics of degradation of enalapril maleate in dosage forms. Acta Pol Pharm 2004;61:415–18
   PubMedGoogle Scholar
• Risha PG, Vervaet C, Vergote G, et al. Drug formulations intended for the global market should be tested for stability under tropical climatic conditions. Eur J Clin Pharmacol 2003;59:135–41
   PubMed Web of Science ®Google Scholar
• Wu Y, Fassihi R. Stability of metronidazole, tetracycline HCl and famotidine alone and in combination. Int J Pharm 2005;290:1–13
   PubMed Web of Science ®Google Scholar
• Mohamad H, Aiache JM, Renoux R, et al. Study on the biopharmaceutical stability of medicines IV. Application to tetracycline hydrochloride capsules. In vivo study. STP Pharm 1987;3:407–11
   Google Scholar
• Nazerali H, Muchemwa T, Hogerzeil HV. Stability of Essential Medicines in Tropical Climates: Zimbabwe. WHO/DAP/94.16. Geneva, Switzerland: WHO 1996
   Google Scholar